Cargando…
Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of b-thalassemia with blood transfusions
β-thalassemia is an inherited anemia characterized by ineffective erythropoiesis. Blood transfusions are required for survival in transfusion-dependent b-thalassemia and are also occasionally needed in patients with non-transfusion-dependent β-thalassemia. Patients with transfusion-dependent b-thala...
Autores principales: | Kalleda, Natarajaswamy, Flace, Anna, Altermatt, Patrick, Ingoglia, Giada, Doucerain, Cédric, Nyffenegger, Naja, Dürrenberger, Franz, Manolova, Vania |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543196/ https://www.ncbi.nlm.nih.gov/pubmed/37165842 http://dx.doi.org/10.3324/haematol.2022.282328 |
Ejemplares similares
-
The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease
por: Nyffenegger, Naja, et al.
Publicado: (2022) -
P1510: VAMIFEPORT PREVENTED THE FORMATION OF NON-TRANSFERRIN-BOUND IRON IN A MOUSE MODEL OF ΒETA-THALASSEMIA WITH BLOOD TRANSFUSIONS
por: Kalleda, N., et al.
Publicado: (2022) -
The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia
por: Nyffenegger, Naja, et al.
Publicado: (2021) -
Structures of ferroportin in complex with its specific inhibitor vamifeport
por: Lehmann, Elena Farah, et al.
Publicado: (2023) -
Erythroferrone exacerbates iron overload and ineffective extramedullary erythropoiesis in a mouse model of β-thalassemia
por: Olivera, Joseph, et al.
Publicado: (2023)